Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: results of a randomised phase III intergroup study initiated by the AIO and AGMT (ML18147)

被引：0
|
作者：
Greil, R. [1 ]
Arnold, D. [2 ]
Hegewisch-Becker, S.
Freier, W.
Steffens, C. -C. [3 ]
Bertram, M.
Schlichting, C. [4 ]
Andel, J. [5 ]
Taylor, M. [6 ]
Makrutzki, M. [7 ]
Kubicka, S. [8 ]
机构：
[1] Paracelsus Med Univ, Salzburg, Austria
[2] UCCH, Hubertus Wald Tumor Ctr, Hamburg, Germany
[3] MVZ Haematol Onkol Klin Dr Hancken, Stade, Germany
[4] Diakoniekrankenhaus gGmbH, Rotenburg, Germany
[5] LKH Steyr, Steyr, Austria
[6] Genentech Inc, Epidemiol Patient Reported Outcomes & Healthcare, San Francisco, CA 94080 USA
[7] F Hoffmann La Roche & Cie AG, Basel, Switzerland
[8] Kleiskliniken Reutlingen GmbH, Med Klin 1, Reutlingen, Germany
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：254 / 254
页数：1
相关论文
共 50 条
  • [1] Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings
    Kubicka, S.
    Greil, R.
    Andre, T.
    Bennouna, J.
    Sastre, J.
    Van Cutsem, E.
    von Moos, R.
    Oesterlund, P.
    Reyes-Rivera, I.
    Mueller, T.
    Makrutzki, M.
    Arnold, D.
    ANNALS OF ONCOLOGY, 2013, 24 (09) : 2342 - 2349
  • [2] Bevacizumab plus chemotherapy continued beyond first disease progression in patients with metastatic colorectal cancer previously treated with bevacizumab-based therapy: Patterns of disease progression and outcomes based on extent of disease in the ML18147 study
    Greil, Richard
    Von Moos, Roger
    Bennouna, Jaafar
    Osterlund, Pia J.
    Andre, Thierry
    Van Cutsem, Eric
    Kubicka, Stefan
    Arnold, Dirk
    de Prado, Jose Maria Vieitez
    Bouche, Olivier
    Alonso, Vicente
    Borg, Christophe
    Schlichting, Christoph
    Steffens, Claus-Christoph
    Osborne, Stuart
    Waterkamp, Daniel
    Makrutzki, Martina
    Sastre, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] EFFICACY AND SAFETY OF TREATMENT WITH BEVACIZUMAB (BEV) plus CHEMOTHERAPY (CT) BEYOND FIRST PROGRESSION IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) PREVIOUSLY TREATED WITH BEV plus CT: AGE SUBGROUP ANALYSIS FROM A RANDOMISED PHASE III INTERGROUP STUDY (ML18147)
    Bouche, O.
    Steffens, C.
    Andre, T.
    Bennouna, J.
    Sastre, J.
    Osterlund, P.
    von Moos, R.
    Reyes-Rivera, I.
    Sersch, M. A.
    Arnold, D.
    ANNALS OF ONCOLOGY, 2012, 23 : 190 - 191
  • [4] Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).
    Arnold, Dirk
    Andre, Thierry
    Bennouna, Jaafar
    Sastre, Javier
    Osterlund, Pia J.
    Greil, Richard
    Van Cutsem, Eric
    Von Moos, Roger
    Reyes-Rivera, Irmarie
    Bendahmane, Belguendouz
    Kubicka, Stefan
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase III trial
    Cochereau, D.
    de Gramont, A.
    ONCOLOGIE, 2013, 15 (05) : 271 - 272
  • [6] Bevacizumab (BEV) continued beyond first progression in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with BEV plus chemotherapy (CT): Biomarker findings from ML18147.
    Kubicka, Stefan
    Von Moos, Roger
    Greil, Richard
    Sastre, Javier
    Osterlund, Pia J.
    Arnold, Dirk
    Andre, Thierry
    Van Cutsem, Eric
    Mueller, Thomas
    Reyes-Rivera, Irmarie
    Bennouna, Jaafar
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [7] Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
    Bennouna, Jaafar
    Sastre, Javier
    Arnold, Dirk
    Osterlund, Pia
    Greil, Richard
    Van Cutsem, Eric
    von Moos, Roger
    Maria Vieitez, Jose
    Bouche, Olivier
    Borg, Christophe
    Steffens, Claus-Christoph
    Alonso-Orduna, Vicente
    Schlichting, Christoph
    Reyes-Rivera, Irmarie
    Bendahmane, Belguendouz
    Andre, Thierry
    Kubicka, Stefan
    LANCET ONCOLOGY, 2013, 14 (01): : 29 - 37
  • [8] RANDOMISED PHASE III STUDY OF BEVACIZUMAB plus CHEMOTHERAPY BEYOND PROGRESSION IN BEVACIZUMAB-TREATED PATIENTS WITH METASTATIC COLORECTAL CANCER: TML STUDY KRAS SUBGROUP FINDINGS
    Van Cutsem, Eric
    Maria Vieitez, Jose
    Bouche, Olivier
    Osterlund, Pia
    Bennouna, Jaafar
    Andre, Thierry
    Sastre, Javier
    Alonso-Orduna, Vicente
    Kubicka, Stefan
    Greil, Richard
    von Moos, Roger
    Reyes-Rivera, Irmarie
    Scherer, Stefan
    Bendahmane, Belguendouz
    Arnold, Dirk
    ANNALS OF ONCOLOGY, 2012, 23 : 15 - 15
  • [9] BEVACIZUMAB (BEV) plus CHEMOTHERAPY (CT) BEYOND FIRST PROGRESSION IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) PREVIOUSLY TREATED WITH BEV-BASED THERAPY: OVERALL SURVIVAL SUBGROUP FINDINGS FROM ML18147
    Vieitez de Prado, J. M.
    Borg, C.
    Arnold, D.
    Greil, R.
    Van Cutsem, E. J. D.
    von Moos, R.
    Bennouna, J.
    Reyes-Rivera, I.
    Bendahmane, B.
    Kubicka, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 193 - 193
  • [10] BEVACIZUMAB plus CHEMOTHERAPY BEYOND FIRST PROGRESSION IN METASTATIC COLORECTAL CANCER PATIENTS PREVIOUSLY TREATED WITH BEVACIZUMAB-BASED THERAPY: TML STUDY SUBGROUP FINDINGS
    Andre, Thierry
    Jose Maria, Vieitez
    Bouche, Olivier
    Bennouna, Jaafar
    Sastre, Javier
    Alonso-Orduna, Vicente
    Arnold, Dirk
    Osterlund, Pia
    Greil, Richard
    Van Cutsem, Eric
    von Moos, Roger
    Reyes-Rivera, Irmarie
    Makrutzki, Martina
    Kubicka, Stefan
    ANNALS OF ONCOLOGY, 2012, 23 : 14 - 14
12345